Sandra Kovachka

This study develops a synthetic cleavage module that selectively degrades pathogenic r(CUG) repeats in cells, reducing DM1-associated pathology without DNA damage.

This study shows that inhibiting PTCH1 drug efflux improves chemotherapy effectiveness in triple-negative breast cancer cells by increasing drug retention and reducing cell migration.

The paper investigates the structure of PTCH1 bound to the inhibitor PAH, revealing its mechanism of blocking drug efflux and providing insights for drug design.

The paper develops a live-cell method to identify RNA-small molecule interactions and uses it to design selective RNA degraders.